Prabhakar Bastola

University of North Carolina at Chapel Hill — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

8h-index315citations15works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Endoplasmic Reticulum Stress and Disease(9), Ubiquitin and proteasome pathways(6), Autophagy in Disease and Therapy(3), Virus-based gene therapy research(3), Cellular transport and secretion(2)

Publications15 total

Inhibition of experimental autoimmune uveitis by intravitreal AAV-Equine-IL10 gene therapy
PLoS ONE·2022· 19 citedOpen Access
Multiple Components of Protein Homeostasis Pathway Can Be Targeted to Produce Drug Synergies with VCP Inhibitors in Ovarian Cancer
Cancers·2022· 6 citedOpen Access
Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy
Viruses·2021· 16 citedOpen Access
Adeno-Associated Virus Mediated Gene Therapy for Corneal Diseases
Pharmaceutics·2020· 47 citedOpen Access
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
Nature Communications·2020· 45 citedOpen Access
Heterozygous mutations in valosin-containing protein (VCP) and resistance to VCP inhibitors
Scientific Reports·2019· 6 citedOpen Access
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
2018· 8 citedOpen Access
Emerging Cancer Therapeutic Targets in Protein Homeostasis
The AAPS Journal·2018· 37 cited
Abstract A40: Specific mutations in the D1-D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors
Clinical Cancer Research·2018
Heterozygous mutations in <i>p97</i> and resistance to p97 inhibitors
2018· 4 citedOpen Access
Targeting vulnerabilities through inhibiting the valosin-containing protein (VCP/p97) in ovarian cancer
KU ScholarWorks (The University of Kansas)·2018Open Access
Co-selected mutations in VCP: a novel mechanism of resistance to VCP inhibitors
Cell Death and Disease·2018· 9 citedOpen Access
Specific mutations in the D1–D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors
Cell Death Discovery·2017· 32 citedOpen Access
Abstract NTOC-119: VCP INHIBITORS INDUCE ENDOPLASMIC RETICULUM (ER) STRESS AND SYNERGISTICALLY KILL OVARIAN CANCER CELLS IN COMBINATION WITH SALUBRINAL OR MIFEPRISTONE
Clinical Cancer Research·2017
VCP inhibitors induce endoplasmic reticulum stress, cause cell cycle arrest, trigger caspase‐mediated cell death and synergistically kill ovarian cancer cells in combination with Salubrinal
Molecular Oncology·2016· 86 citedOpen Access

Frequent Co-authors

Jeremy Chien(9), Liujiang Song(3), Matthew L. Hirsch(3), Frank J. Schoenen(2), Brian C. Gilger(2), Hector H. Huang(2), Ian Ferguson(2), Alexis M. Thornton(2), Christine Lam(2), Yu-Hsiu T. Lin(2), Priya Choudhry(2), Margarette C. Mariano(2), Makeba Marcoulis(2), Julia Malato(2), Paul Phojanakong(2), Thomas Martin(2), Jeffrey L. Wolf(2), Sandy W. Wong(2), Nina Shah(2), Byron Hann(2)